IMMUNOTECH-B (06978.HK) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Annual Results

Bulletin Express

Mar 10

Immunotech Biopharm Ltd (stock code: 06978, traded as IMMUNOTECH-B) has notified the market that its board of directors will convene on 20 March 2026. The meeting’s primary agenda is to consider and approve the consolidated annual results of the Company and its subsidiaries for the financial year ended 31 December 2025, with a view to releasing these figures for public disclosure.

The announcement, dated 10 March 2026, was signed by Chairman and Executive Director Tan Zheng. The current Board comprises:

• Executive Director: Tan Zheng • Non-executive Directors: Yang Fan, Wang Ruihua, Wang Donghu, Yang Xin, Liu Rui, and Cao Ran • Independent Non-executive Directors: Professor Wang Yingdian, Ng Chi Kit, Peng Sujiu, and Zhang Guoguang

No further financial metrics or performance details were provided in the notice. The forthcoming board meeting will determine the Company’s audited results for FY2025, which will be published subsequently in accordance with Hong Kong listing regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118209478"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118209478\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118209478?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118209478","market":"us","top_or_hot":-1,"title":"IMMUNOTECH-B (06978.HK) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Annual Results","media":"Bulletin Express","content":"<p>Immunotech Biopharm Ltd (stock code: 06978, traded as IMMUNOTECH-B) has notified the market that its board of directors will convene on 20 March 2026. The meeting’s primary agenda is to consider and approve the consolidated annual results of the Company and its subsidiaries for the financial year ended 31 December 2025, with a view to releasing these figures for public disclosure.</p>\n<p>The announcement, dated 10 March 2026, was signed by Chairman and Executive Director Tan Zheng. The current Board comprises:</p>\n<p>• Executive Director: Tan Zheng  \n• Non-executive Directors: Yang Fan, Wang Ruihua, Wang Donghu, Yang Xin, Liu Rui, and Cao Ran  \n• Independent Non-executive Directors: Professor Wang Yingdian, Ng Chi Kit, Peng Sujiu, and Zhang Guoguang</p>\n<p>No further financial metrics or performance details were provided in the notice. The forthcoming board meeting will determine the Company’s audited results for FY2025, which will be published subsequently in accordance with Hong Kong listing regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNOTECH-B (06978.HK) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Annual Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNOTECH-B (06978.HK) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Annual Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-10 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Immunotech Biopharm Ltd (stock code: 06978, traded as IMMUNOTECH-B) has notified the market that its board of directors will convene on 20 March 2026. The meeting’s primary agenda is to consider and approve the consolidated annual results of the Company and its subsidiaries for the financial year ended 31 December 2025, with a view to releasing these figures for public disclosure.</p>\n<p>The announcement, dated 10 March 2026, was signed by Chairman and Executive Director Tan Zheng. The current Board comprises:</p>\n<p>• Executive Director: Tan Zheng  \n• Non-executive Directors: Yang Fan, Wang Ruihua, Wang Donghu, Yang Xin, Liu Rui, and Cao Ran  \n• Independent Non-executive Directors: Professor Wang Yingdian, Ng Chi Kit, Peng Sujiu, and Zhang Guoguang</p>\n<p>No further financial metrics or performance details were provided in the notice. The forthcoming board meeting will determine the Company’s audited results for FY2025, which will be published subsequently in accordance with Hong Kong listing regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06978","symbol_name":"永泰生物-B","start_time":0,"source_url":"","article_id":"1118209478","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118209478","pubTimestamp":1773138180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Immunotech Biopharm Ltd (stock code: 06978, traded as IMMUNOTECH-B) has notified the market that its board of directors will convene on 20 March 2026. The meeting’s primary agenda is to consider and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06978":"永泰生物-B"},"translate_title":"IMMUNOTECH-B(06978.HK)定于2026年3月20日召开董事会批准2025财年全年业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06978":1},"content_text":"Immunotech Biopharm Ltd (stock code: 06978, traded as IMMUNOTECH-B) has notified the market that its board of directors will convene on 20 March 2026. The meeting’s primary agenda is to consider and approve the consolidated annual results of the Company and its subsidiaries for the financial year ended 31 December 2025, with a view to releasing these figures for public disclosure.\nThe announcement, dated 10 March 2026, was signed by Chairman and Executive Director Tan Zheng. The current Board comprises:\n• Executive Director: Tan Zheng  \n• Non-executive Directors: Yang Fan, Wang Ruihua, Wang Donghu, Yang Xin, Liu Rui, and Cao Ran  \n• Independent Non-executive Directors: Professor Wang Yingdian, Ng Chi Kit, Peng Sujiu, and Zhang Guoguang\nNo further financial metrics or performance details were provided in the notice. The forthcoming board meeting will determine the Company’s audited results for FY2025, which will be published subsequently in accordance with Hong Kong listing regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}